Analysts Set Expectations for electroCore Q3 Earnings

Key Points

• Brookline Capital Markets modestly raised its Q3 2026 EPS estimate for electroCore to a loss of $0.27 per share from $0.28, while forecasting Q4 and full-year 2026 losses of $0.22 and $1.39 per share, respectively.
• electroCore reported a Q2 loss of $0.33 per share, beating the $0.42 consensus estimate, although revenue of $9.45 million was slightly below expectations and the company remained unprofitable.
• The stock was up 10.8%, but analyst sentiment remained mixed: MarketBeat showed a consensus “Hold” rating with an $18 target price, while Weiss Ratings maintained a “sell” rating. Institutional investors own 26.74% of the shares.

electroCore, Inc. (NASDAQ:ECOR - Free Report) - Research analysts at Brookline Capital Markets upped their Q3 2026 EPS estimates for shares of electroCore in a report issued on Friday, August 7th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings of ($0.27) per share for the quarter, up from their previous estimate of ($0.28). The consensus estimate for electroCore's current full-year earnings is ($1.48) per share. Brookline Capital Markets also issued estimates for electroCore's Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($1.39) EPS.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of electroCore in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, electroCore presently has a consensus rating of "Hold" and a consensus target price of $18.00.

electroCore Stock Up 10.8%

ECOR stock opened at $8.96 on Tuesday. The stock has a market capitalization of $80.82 million, a P/E ratio of -5.40 and a beta of 0.93. The firm has a 50-day simple moving average of $7.67 and a 200-day simple moving average of $7.01. electroCore has a 52 week low of $4.16 and a 52 week high of $10.49.

electroCore (NASDAQ:ECOR - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.09. electroCore had a negative net margin of 39.96% and a negative return on equity of 1,956.38%. The business had revenue of $9.45 million for the quarter, compared to the consensus estimate of $9.49 million.

Institutional Trading of electroCore

A number of hedge funds and other institutional investors have recently modified their holdings of ECOR. Cubist Systematic Strategies LLC acquired a new stake in shares of electroCore during the 1st quarter worth approximately $153,000. Two Sigma Investments LP lifted its stake in electroCore by 20.8% during the 3rd quarter. Two Sigma Investments LP now owns 24,603 shares of the company's stock worth $122,000 after acquiring an additional 4,231 shares in the last quarter. WealthShield Partners LLC purchased a new position in shares of electroCore in the first quarter valued at approximately $157,000. Jane Street Group LLC boosted its position in electroCore by 114.4% in the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company's stock valued at $246,000 after buying an additional 19,599 shares during the period. Finally, DRW Securities LLC purchased a new position in electroCore in the fourth quarter valued at $264,000. 26.74% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at electroCore

In related news, CFO Joshua S. Lev sold 6,667 shares of the business's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $9.00, for a total transaction of $60,003.00. Following the transaction, the chief financial officer directly owned 84,889 shares in the company, valued at approximately $764,001. The trade was a 7.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Thomas J. Errico acquired 9,992 shares of the company's stock in a transaction that occurred on Thursday, May 21st. The shares were acquired at an average cost of $5.99 per share, with a total value of $59,852.08. Following the purchase, the director owned 360,071 shares in the company, valued at $2,156,825.29. This represents a 2.85% increase in their position. The disclosure for this purchase is available in the SEC filing. 7.80% of the stock is owned by corporate insiders.

Key electroCore News

Here are the key news stories impacting electroCore this week:

• Positive Sentiment: HC Wainwright raised its fiscal 2026 EPS forecast to -$1.34 from -$1.49, while Brookline Capital Markets increased its estimate to -$1.39 from -$1.43. Both firms also made slightly less pessimistic forecasts for third-quarter 2026 earnings.
• Positive Sentiment: HC Wainwright improved its estimates for the first and second quarters of 2027, forecasting losses of $0.22 and $0.30 per share, respectively, compared with prior estimates of $0.37 per share losses for both periods.
• Neutral Sentiment: Despite the upward revisions, analysts still expect substantial losses: HC Wainwright projects fiscal 2027 EPS of -$0.81, versus the current-year consensus estimate of -$1.48. The firm’s longer-range forecasts anticipate a return to profitability in 2029, followed by $0.65 EPS in 2030.
• Negative Sentiment: HC Wainwright cut its fiscal 2027 EPS forecast to -$0.81 from -$0.67 and reduced its fiscal 2028 estimate to -$0.39 from -$0.13, extending the expected period of losses.
• Negative Sentiment: Long-term estimates were sharply lowered: fiscal 2029 EPS was reduced to $0.15 from $0.36, and fiscal 2030 EPS to $0.65 from $0.90. HC Wainwright also lowered its fourth-quarter 2026 and third-quarter 2027 forecasts.

electroCore Company Profile

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company's lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source